{"id":56972,"date":"2024-02-27T17:16:42","date_gmt":"2024-02-27T17:16:42","guid":{"rendered":"https:\/\/medsname.com\/ezedoc\/"},"modified":"2026-08-28T11:51:18","modified_gmt":"2026-08-28T11:51:18","slug":"ezedoc","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/ezedoc\/","title":{"rendered":"Ezedoc"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 0 0 24px 0; border-radius: 4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin: 0 0 8px 0; font-size: 16px; font-weight: bold;\">\u26a1 Quick Answer \u2014 What is Ezedoc?<\/h3>\n<p style=\"margin: 0;\"><strong>Ezedoc<\/strong> inneholder <strong>ezetimibe<\/strong> (10 mg), et <strong>kolesterolabsorpsjonshemmer<\/strong> som blokkerer NPC1L1-transport\u00f8ren i tynntarmen. Det er <strong>go-to add-on therapy when a statin alone doesn\u2019t get LDL to target<\/strong>. On its own, ezetimibe lowers LDL-C by about 17\u201322%. Added to a statin, it produces an additional ~20\u201325% LDL reduction, totaling a 55\u201360% fall \u2014 equivalent to doubling the statin dose without the dose-related muscle or liver side effects. The <strong>IMPROVE-IT<\/strong> trial (18,144 patients post-ACS) proved that adding ezetimibe to simvastatin further reduces cardiovascular events. Dose: 10\u00a0mg once daily, any time, with or without food. Generally very well-tolerated \u2014 mild GI upset, occasional myalgia, rare transaminase elevation. Avoid in severe hepatic impairment.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Hva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte <a href=\"https:\/\/medsbase.com\/nb\/reviews\/\">kundeanmeldelser<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Hver ordre er dekket av v\u00e5r <a href=\"https:\/\/medsbase.com\/nb\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>V\u00e5re generiske legemidler er hentet fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskr\u00e9, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 pakkens utside. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskriftsbeskrivelser inkluderer en regulert kortbetalingsbehandler \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel aksepteres ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">Hva er Ezedoc?<\/h2>\n<p>Ezedoc er et oralt lipidsenkende legemiddel som inneholder <strong>ezetimibe<\/strong> (10 mg), produsert av en WHO-GMP-sertifisert produsent. Leveres i pakninger med 30, 60, 90 eller 180 tabletter. Ezetimibe er det f\u00f8rste og eneste legemiddelet i <strong>kolesterolabsorpsjonshemmer<\/strong> klassen. Opprinnelig merkevare: <strong>Zetia \/ Ezetrol<\/strong> (Merck, 2002).<\/p>\n<p>Ezetimibe is a mainstay of second-line lipid management \u2014 the first choice when you need more LDL reduction than a tolerated statin dose provides, or when a patient cannot tolerate higher statin doses. It is also the most common partner in fixed-dose combinations (simvastatin\/ezetimibe = Inegy\/Vytorin; rosuvastatin\/ezetimibe = various).<\/p>\n<h2 class=\"wp-block-heading\">Hva brukes Ezedoc til?<\/h2>\n<ul>\n<li><strong>Prim\u00e6r hyperkolesterolemi<\/strong> \u2014 as add-on to a statin when LDL is not at goal on the maximum tolerated statin dose<\/li>\n<li><strong>Statinintoleranse<\/strong> \u2014 as monotherapy or with a very low statin dose when a full statin dose causes muscle or liver problems<\/li>\n<li><strong>Familial hyperkolesterolemi<\/strong> (heterozygous and homozygous) \u2014 in combination with statin<\/li>\n<li><strong>Sekund\u00e6rforebygging etter akutt koronarsyndrom<\/strong> \u2014 add to statin to further reduce CV events (IMPROVE-IT trial)<\/li>\n<li><strong>Sitosterolemi<\/strong> \u2014 a rare genetic condition where ezetimibe is disease-modifying<\/li>\n<\/ul>\n<p>Ezetimibe is weak as a monotherapy (~17% LDL reduction) compared to a statin (~30\u201360%); it is most powerful as an add-on.<\/p>\n<h2 class=\"wp-block-heading\">Hvordan virker Ezedoc?<\/h2>\n<p>Ezetimibe hemmer selektivt <strong>Niemann-Pick C1-Like 1 (NPC1L1)-transport\u00f8ren<\/strong> p\u00e5 enterocytter i den proximale tynntarmen. NPC1L1 er ansvarlig for opptak av kostholdsmessig og gallesyk kolesterol fra tarmlumen inn i enterocytten.<\/p>\n<p>Med NPC1L1 blokkert:<\/p>\n<ul>\n<li><strong>Tarmens kolesterolopptak synker med ~54%<\/strong><\/li>\n<li><strong>Hepatiske kolesterolreserver minker<\/strong> fordi mindre kolesterol n\u00e5r leveren<\/li>\n<li><strong>LDL-reseptorer oppreguleres<\/strong> on hepatocytes \u2014 the liver pulls more LDL out of the blood<\/li>\n<li><strong>Plasma LDL-C falls by 17\u201322%<\/strong> som monoterapi; opptil 25% ekstra n\u00e5r kombinert med et statin<\/li>\n<li>HMG-CoA reduktase-aktivitet (statinets m\u00e5l) er uendret<\/li>\n<\/ul>\n<p>Fordi ezetimibe og statiner virker p\u00e5 <strong>komplement\u00e6re mekanismer<\/strong> (absorption vs synthesis), their effects are additive. Statins reduce LDL synthesis; ezetimibe reduces LDL absorption\/input. Together they drop LDL more than either can alone, without adding to each other\u2019s side-effect profile.<\/p>\n<p>Resultatdata: <strong>IMPROVE-IT-studien<\/strong> (2015) viste at tillegg av ezetimib til simvastatin hos pasienter etter akutt koronarsyndrom reduserte den sammensatte kardiovaskul\u00e6re endepunktet med 6,4 % (NNT 50 over 7 \u00e5r), noe som bekrefter at LDL-senkningen gir reell reduksjon i hendelser.<\/p>\n<h2 class=\"wp-block-heading\">Dosering og administrering<\/h2>\n<p><strong>Standard dose:<\/strong> 10\u00a0mg once daily at any time of day, with or without food.<\/p>\n<ul>\n<li>Ta til samme tidspunkt hver dag for bedre f\u00f8lgetrofasthet.<\/li>\n<li>Can be taken at the same time as a statin or spaced out \u2014 no timing interaction.<\/li>\n<li>Miss a dose \u2014 take it as soon as you remember unless close to the next; do not double up.<\/li>\n<li>Ingen dosejustering n\u00f8dvendig ved nyresvikt eller mild til moderat leversvikt.<\/li>\n<li>Monitor lipid panel and ALT at baseline and 6\u20138 weeks after starting. Check CK only if symptoms.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bivirkninger<\/h2>\n<p>Ezetimib er et av de best tolererte lipidsenkende legemidlene. Bivirkningsfrekvensen er n\u00e6r placebosatser i studier.<\/p>\n<p><strong>Vanlig (&lt; 5 %):<\/strong><\/p>\n<ul>\n<li>Mild diar\u00e9, flatulens<\/li>\n<li>\u00d8vre luftveisinfeksjon, bihulebetennelse<\/li>\n<li>Tretthet<\/li>\n<li>Artralgi<\/li>\n<\/ul>\n<p><strong>Mindre vanlig:<\/strong><\/p>\n<ul>\n<li>Transaminase elevation \u2014 usually small; more common when combined with a statin<\/li>\n<li>Muscle pain, myalgia, myopathy \u2014 rare; primarily when combined with statin<\/li>\n<li>Overf\u00f8lsomhet, angio\u00f8dem, utslett<\/li>\n<li>Pancreatitis \u2014 very rare<\/li>\n<li>Cholelithiasis \u2014 very rare<\/li>\n<li>Thrombocytopenia \u2014 very rare<\/li>\n<li>Rhabdomyolysis \u2014 exceedingly rare, almost always in combination with a statin<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Legemiddelinteraksjoner<\/h2>\n<ul>\n<li><strong>Cyclosporine<\/strong> \u2014 significantly raises ezetimibe levels (and vice versa). Monitor cyclosporine levels; some guidance suggests avoiding.<\/li>\n<li><strong>Gallesyrebindende midler<\/strong> (cholestyramine, colestipol) \u2014 reduce ezetimibe absorption; take ezetimibe at least 2 hours before or 4 hours after.<\/li>\n<li><strong>Warfarin<\/strong> \u2014 occasional INR change reported; monitor when starting.<\/li>\n<li><strong>Statiner<\/strong> \u2014 no adverse PK interaction; this combination is the therapeutic mainstay.<\/li>\n<li><strong>Fibrater<\/strong> \u2014 fenofibrate\/ezetimibe combination is safe; gemfibrozil raises ezetimibe levels and is generally avoided.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Hvem b\u00f8r ikke ta Ezedoc?<\/h2>\n<ul>\n<li>Moderat til alvorlig leverfunksjonssvikt (ved kombinasjon med statin)<\/li>\n<li>Active liver disease or persistent transaminase elevation &gt; 3\u00d7 ULN<\/li>\n<li>Graviditet (ved kombinasjon med statin)<\/li>\n<li>Amming<\/li>\n<li>Barn under 10 \u00e5r (utilstrekkelig data)<\/li>\n<li>Kjent overf\u00f8lsomhet mot ezetimib<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Oppbevaring<\/h2>\n<p>Store Ezedoc below 25\u00b0C in a dry place, in the original blister. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Vanlige sp\u00f8rsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">Kan jeg ta Ezedoc i stedet for et statin?<\/h3>\n<p>Usually no. As monotherapy, ezetimibe lowers LDL by only ~17% \u2014 much less than a statin (30\u201360%). It is appropriate as monotherapy only for patients who cannot tolerate any statin at any dose. For most people, the best lipid-lowering strategy is statin first, ezetimibe added if LDL is still above target.<\/p>\n<h3 class=\"wp-block-heading\">Hvordan sammenligner Ezedoc med \u00e5 doble statindosen min?<\/h3>\n<p>Doubling a statin dose typically adds ~6% LDL reduction (the statin \u201crule of 6\u201d). Adding ezetimibe adds ~20\u201325% LDL reduction. <strong>Adding ezetimibe is 3\u20134\u00d7 more effective<\/strong> enn \u00e5 doble statindosen, og uten doseavhengig \u00f8kning i muskelsymptomer. Dette er grunnen til at moderne retningslinjer foretrekker kombinasjonen statin + ezetimib fremfor \u00e5 \u00f8ke statindosen til maksimum.<\/p>\n<h3 class=\"wp-block-heading\">Reduserer Ezedoc hjerneslag og hjerteinfarkt?<\/h3>\n<p>Yes \u2014 the IMPROVE-IT trial (18,144 post-ACS patients) showed adding ezetimibe to simvastatin reduced the composite endpoint of CV death, MI, unstable angina, revascularisation, or stroke by 6.4% over 7 years. This is the landmark evidence that LDL reduction beyond statins alone still translates into real cardiovascular benefit.<\/p>\n<h3 class=\"wp-block-heading\">N\u00e5r b\u00f8r jeg ta Ezedoc?<\/h3>\n<p>Any time of day is fine. Unlike simvastatin (evening preferred), ezetimibe timing is not dose-dependent \u2014 pick a time you will remember consistently. Many patients take it at the same time as their statin.<\/p>\n<h3 class=\"wp-block-heading\">For\u00e5rsaker Ezedoc muskelsmerter som statiner?<\/h3>\n<p>Sjelden. Ezetimib som monoterapi viser muskelsideeffekter p\u00e5 placebo-niv\u00e5. N\u00e5r det kombineres med et statin, \u00f8ker det ikke meningsfullt statinrelaterte muskelsymptomer sammenlignet med statinet alene.<\/p>\n<h3 class=\"wp-block-heading\">Hvor kan jeg kj\u00f8pe Ezedoc p\u00e5 nettet?<\/h3>\n<p>Du kan bestille Ezedoc (10 mg) fra MedsBase i pakninger med 30, 60, 90 eller 180 tabletter. Vi sender over hele verden med diskr\u00e9 emballasje og ekte WHO-GMP-sertifisert produsentbeholdning.<\/p>\n<h2 class=\"wp-block-heading\">Relaterte kolesterolmedisiner<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/lipvas\/\">Lipvas \u2014 Atorvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/crestor\/\">Crestor \u2014 Rosuvastatin 5\/10\/20 mg (AstraZeneca)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/rosuline\/\">Rosuline \u2014 Rosuvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/atorvatin\/\">Atorvatin \u2014 Atorvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/pivasta\/\">Pivasta \u2014 Pitavastatin (interaction-clean)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/lipicard\/\">Lipicard \u2014 Fenofibrate (for triglycerides)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/high-cholesterol-treatments\/\"><strong>Se alle h\u00f8ykolesterolmedisiner<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background: #fff3f3; border-left: 4px solid #d9534f; padding: 16px 20px; margin: 24px 0; border-radius: 4px;\"><strong>\u2695 Medical Disclaimer.<\/strong> Denne siden er kun til informasjonsform\u00e5l og erstatter ikke medisinsk r\u00e5dgivning fra en kvalifisert helsepersonell. Uforklarlige muskelsmerter, gulfarging av hud eller \u00f8yne, eller alvorlige magesmerter krever umiddelbar medisinsk vurdering.<\/div>\n<h3 class=\"wp-block-heading\">Hvorfor bestille fra MedsBase<\/h3>\n<p>Ezedoc leveres gjennom en WHO-GMP-sertifisert produsent med full COA-dokumentasjon. Vi sender over hele verden i enkel, diskr\u00e9 emballasje, og hver bestilling er dekket av v\u00e5r <a href=\"\/nb\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. Your statement descriptor when paying by card shows the regulated payment processor (a regulated card-payment processor), never \u201cMedsBase\u201d or any medication name.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterte alternativer<\/h3>\n<p>Andre produkter innen <strong>Kroniske tilstander<\/strong> som kunder ogs\u00e5 ser p\u00e5:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/bencid\/\">Bencid<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/tiova-rotacaps\/\">Tiova Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/serobid-rotacaps\/\">Serobid Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/headset\/\">Headset<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/xafinact\/\">Xafinact<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Senker kolesterolniv\u00e5et<br \/>\n\u2705 Reduserer risiko for hjerte- og karsykdom<br \/>\n\u2705 Forebygger \u00e5reforkalkning<br \/>\n\u2705 Foreskrevet av leger<br \/>\n\u2705 Oral medikasjon som alternativ<\/p>\n<p><strong>Ezedoc<\/strong> inneholder <strong>Ezetimibe<\/strong>.<\/p>","protected":false},"featured_media":56973,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3953],"product_tag":[4210,4211],"class_list":{"0":"post-56972","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-high-cholesterol-treatments","9":"product_tag-ezedoc","10":"product_tag-ezetimibe","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product\/56972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/comments?post=56972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media\/56973"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media?parent=56972"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_brand?post=56972"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat?post=56972"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_tag?post=56972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}